Aquestive Therapeutics, Inc. Common Stock
AQST Real Time Price USDRecent trades of AQST by members of U.S. Congress
|
Name
|
Type
|
Shares
|
Price
|
Shares Held
|
Date
|
Reported
|
|---|
|
Investor
|
Shares
|
Change in Shares
|
Market Value
|
Date
|
Reported
|
|---|
|
Investor
|
Type
|
Shares
|
Change in Shares
|
Market Value
|
Date
|
Reported
|
|---|
Recently reported changes by institutional investors
Quarterly net insider trading by AQST's directors and management
* Insider trading data parsed from SEC Form 4 filings by Quiver Quantitative. Sign up for the Quiver API for real-time access.
- 1M
- 3M
- 6M
- YTD
- 1Y
- 2Y
- 5Y
- MAX
About
Key Metrics
Return (1d)
Return (30d)
Return (1Y)
CAGR (Total)
Max Drawdown
Beta
Alpha
Sharpe Ratio
Win Rate
Average Win
Average Loss
Annual Volatility
Annual Std Dev
Information Ratio
Treynor Ratio
Total Trades
Metrics Definitions
-
Alpha
Measures a portfolio's risk-adjusted performance against that of its benchmark
Learn More -
Annual Standard Deviation
Measures how much the portfolio's total return varies from its mean or average.
Learn More -
Annual Volatility
A statistical measure of the dispersion of returns for the portfolio.
Learn More -
Average Win
The average return (%) for trades that resulted in a positive return.
-
Average Loss
The average return (%) for trades that resulted in a negative return.
-
Beta
A measure of the volatility of the portfolio compared to the market as a whole.
Learn More -
CAGR
CAGR (Compounded Annual Growth Rate), is the historical annualized rate of return for an investment strategy, throughout the backtest period.
Learn More -
Information Ratio
A measurement of portfolio returns beyond the returns of its benchmark compared to the volatility of those returns.
Learn More -
Max Drawdown
the maximum observed loss from a peak to a trough of a portfolio, before a new peak is attained.
Learn More -
Sharpe Ratio
The Sharpe Ratio is a measure of historical risk-adjusted return, which quantifies the amount of return that an investor received per unit of risk.
Learn More -
Total Trades
The total number of trades made by this strategy.
-
Treynor Ratio
Attempts to measure how successful an investment is in providing compensation to investors for taking on investment risk.
Learn More -
Win Rate
The percentage of total trades that resulted in a positive return.
Be the first to see our newest insights and key updates across all datasets.
Government lobbying spending instances
Estimated quarterly lobbying spending
AQST Revenue by Segment or Geography
New patents grants
-
Patent Title: System and method for making personalized individual unit doses containing pharmaceutical actives Dec. 24, 2024
-
Patent Title: Enhanced delivery epinephrine compositions Jul. 02, 2024
-
Patent Title: System and method for making personalized individual unit doses containing pharmaceutical actives Nov. 07, 2023
-
Patent Title: Oral film compositions and dosage forms having precise active dissolution profiles Jan. 03, 2023
-
Patent Title: Pharmaceutical compositions with enhanced permeation Mar. 15, 2022
-
Patent Title: Process for manufacturing a resulting pharmaceutical film Dec. 28, 2021
-
Patent Title: Enhanced delivery epinephrine compositions Dec. 07, 2021
-
Patent Title: Enhanced delivery epinephrine compositions Nov. 02, 2021
-
Patent Title: Dual lane coating Sep. 28, 2021
-
Patent Title: Uniform films for rapid-dissolve dosage form incorporating anti-tacking compositions Aug. 03, 2021
-
Patent Title: Reduction in stress cracking of films Mar. 16, 2021
-
Patent Title: Manufacturing of small film strips Mar. 09, 2021
-
Patent Title: Thin film with non-self-aggregating uniform heterogeneity and drug delivery systems made therefrom Jan. 12, 2021
-
Patent Title: Sublingual and buccal film compositions Nov. 03, 2020
-
Patent Title: Process for manufacturing a resulting pharmaceutical film Aug. 04, 2020
-
Patent Title: Reduction in stress cracking of films Nov. 05, 2019
-
Patent Title: Manufacturing of small film strips Apr. 30, 2019
-
Patent Title: Thin film with non-self-aggregating uniform heterogeneity and drug delivery systems made therefrom Oct. 30, 2018
-
Patent Title: Sublingual and buccal film compositions Jul. 31, 2018
Federal grants, loans, and purchases
Estimated quarterly amount awarded from public contracts
Recent insights relating to AQST
Recent picks made for AQST stock on CNBC
ETFs with the largest estimated holdings in AQST
- ... Highest Price Target
- ... Median Price Target
- ... Lowest Price Target
|
Analyst
|
Firm
|
Current
|
Previous
|
Date
|
|---|
- Is $AQST stock a Buy, Sell, or Hold?
- What is the price target for $AQST stock?
* Analyst consensus is not financial advice. Please see our data disclaimers .
|
Shareholder
|
Shares Held
|
|---|
- Who owns $AQST stock?
- Who owns the most shares of $AQST stock?
- What funds own $AQST stock?
* These are estimates based on data taken from SEC filings. There may be inaccuracies due to parsing errors, accidental double-counting, incorrect classification of indirectly owned shares, or any other number of issues.
The Quiver Smart Score combines our data on Congress Trading, Lobbying, Insider Trading, CNBC Mentions and more to provide a comprehensive view of the strength of a stock's underlying data.
The Smart Score grades stocks on a scale of 1 (weakest) to 10 (strongest) based on the strength of the underlying data.Sign Up to view AQST Smart Score
See concise summaries of analyst reports, presenting both bullish and bearish arguments for a stock.
Example:
The Bulls Say summary highlights positive aspects of the stock.
The Bears Say summary points out potential risks and negative aspects of the stock.